Agendia's Pipeline, Test Business Could Benefit From Companion-Dx Deal with AstraZeneca, NKI | GenomeWeb

By Justin Petrone

A recent companion diagnostics deal that Agendia has penned with AstraZeneca and the Netherlands Cancer Institute could help the Dutch firm validate and expand its test menu, according to its CEO.

Bernhard Sixt said there are a "number of possible outcomes" from the collaboration, some of which may "benefit" ColoPrint, Agendia's in-development colorectal cancer diagnostic, as well as other tests in its pipeline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.